What is Zacks Research’s Forecast for Senestech Q2 Earnings?

Senestech, Inc. (NASDAQ:SNES) – Stock analysts at Zacks Research issued their Q2 2026 earnings per share estimates for Senestech in a research report issued on Wednesday, May 27th. Zacks Research analyst M. Marin anticipates that the company will post earnings per share of ($0.33) for the quarter. The consensus estimate for Senestech’s current full-year earnings is ($1.57) per share. Zacks Research also issued estimates for Senestech’s Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.37) EPS and FY2027 earnings at ($1.06) EPS.

Senestech (NASDAQ:SNES) last issued its earnings results on Tuesday, May 12th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.02. The firm had revenue of $0.49 million during the quarter, compared to analysts’ expectations of $0.63 million. Senestech had a negative return on equity of 67.60% and a negative net margin of 304.22%.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senestech in a research report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Senestech has an average rating of “Hold”.

Senestech Price Performance

Shares of SNES stock opened at $1.79 on Friday. The stock has a market cap of $9.49 million, a P/E ratio of -0.95 and a beta of 0.18. Senestech has a one year low of $1.41 and a one year high of $6.24. The stock has a fifty day moving average price of $1.66 and a 200 day moving average price of $2.08. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.91 and a quick ratio of 7.79.

Insider Transactions at Senestech

In related news, major shareholder Glenbrook Capital Management acquired 146,249 shares of the company’s stock in a transaction on Friday, March 13th. The stock was purchased at an average cost of $1.95 per share, for a total transaction of $285,185.55. Following the completion of the purchase, the insider directly owned 865,850 shares of the company’s stock, valued at $1,688,407.50. The trade was a 20.32% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired 209,154 shares of company stock worth $392,773 in the last three months. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SNES. Sabby Management LLC raised its stake in Senestech by 195.4% during the fourth quarter. Sabby Management LLC now owns 210,564 shares of the company’s stock worth $451,000 after acquiring an additional 139,281 shares in the last quarter. DRW Securities LLC raised its stake in Senestech by 171.1% during the fourth quarter. DRW Securities LLC now owns 82,107 shares of the company’s stock worth $176,000 after acquiring an additional 51,818 shares in the last quarter. Renaissance Technologies LLC raised its stake in Senestech by 35.2% during the fourth quarter. Renaissance Technologies LLC now owns 142,800 shares of the company’s stock worth $306,000 after acquiring an additional 37,165 shares in the last quarter. Jane Street Group LLC acquired a new position in Senestech during the second quarter worth $161,000. Finally, Millennium Management LLC acquired a new stake in shares of Senestech in the third quarter valued at $126,000. 5.19% of the stock is currently owned by institutional investors and hedge funds.

Senestech Company Profile

SenesTech, Inc (NASDAQ: SNES) is a biotechnology company specializing in non-lethal pest management solutions. The company’s core focus is the development and commercialization of fertility-based control methods for commensal rodents, providing an alternative to traditional rodenticides. By targeting the reproductive cycle of rats, SenesTech aims to reduce rodent populations over time without the use of toxic chemicals, offering a more sustainable approach for pest management professionals.

The company’s flagship product, ContraPest®, is an EPA-registered liquid bait that disrupts rodent reproduction.